Skip to main content

Advertisement

Table 2 Clinical features of the 111 systemic lupus erythematosus (SLE) patients

From: Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study

Clinical variables Value
Duration SLE since diagnosis, years 9.0 (5.0 to 17.0) (range 0 to 40)
Systolic blood pressure, mmHg 127.7 (20.1)
Diastolic blood pressure, mmHg 78.7 (12.1)
A history of lupus nephritis, n (%) 38 (34.2%)
SLEDAI 2.0 (0 to 5.25) (range 0 to 27)
SLICC index 1 (0 to 3) (range 0 to 8)
Complement C3, g/l 0.93 (0.22)
Complement C4, g/l 0.17 (0.12 to 0.23)
Complement C1q, mg/l 88.6 (28.1)
Treatment variables  
Current use of immune-modulatory treatment, n (%) 94 (84.7%)
Glucocorticoids 67 (60.4%)
Glucocorticoid dose (mg/day) 5.0 (3.75 to 10.0)
Antimalarial 53 (47.7%)
Azathioprine 24 (21.6%)
Mycophenolatmofetil 9 (8.1%)
Cyclosporine A 7 (6.3%)
Methotrexate 10 (9%)
No disease-modifying anti-rheumatic drugs 17 (15.3%)
Ever use of glucocorticoids, n (%) 99 (89.2%)
Total duration of glucocorticoid use, months 54 (14 to 113)
Total glucocorticoid cumulative dose, g 11.4 (3.5 to 24.5)
Average glucocorticoid dose, mg/day 4.3 (3.4)
Last year glucocorticoid cumulative dose, g 1.4 (0 to 2,3)
Last year glucocorticoid average dose, mg/day 3.8 (0 to 6.3)
  1. Values are number (percent), mean (SD) or median (IQR) when not indicated otherwise. SLEDAI, SLE disease activity index; SLICC, Systemic Lupus International Collaborating Clinics.